Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19194800 | 0.95 | RAB9A (0.60) | RAB9AGAACA9GABRA2GABRB2 | |
| SCHEMBL21044388 | 0.84 | SLC6A3 (0.51) | RAB9AGAAMAPTHTTSMN1; SMN2 | |
| SCHEMBL31315668 | 0.82 | CYP1A2 (0.59) | RAB9AGAACA9GABRA2GABRB2 | |
| SCHEMBL31751612 | 0.81 | GAA (0.48) | RAB9AGAACA9GABRA2GABRB2 | |
| SCHEMBL19180346 | 0.81 | CYP1A2 (0.57) | RAB9AGAAGABRA2GABRB2MAPT | |
| SCHEMBL28362521 | 0.81 | KCNJ1 (0.64) | RAB9AGAACA9ARMAPT | |
| SCHEMBL17594960 | 0.81 | CYP1A2 (0.57) | CA9GABRA2GABRB2MAPTSMN1; SMN2 | |
| SCHEMBL15379503 | 0.81 | CA9 (0.64) | RAB9AGAACA9GABRA2GABRB2 | |
| SCHEMBL17595047 | 0.80 | GABRA2 (0.59) | GABRA2GABRB2MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL17595262 | 0.80 | HTT (0.58) | RAB9AGAAGABRA2GABRB2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191451-B1 | 4-SUBSTITUTED PYRIDINE-2,6-DICARBOXYLIC ACID DERIVATIVES AND METHOD OF PREPARING SAME | OKINAWA INST SCIENCE & TECH SCHOOL CORP (JP) | 2019-06-05 | — | — | EP | disclosed |
| EP-3191451-B1 | 4-SUBSTITUTED PYRIDINE-2,6-DICARBOXYLIC ACID DERIVATIVES AND METHOD OF PREPARING SAME | OKINAWA INST SCIENCE & TECH SCHOOL CORP (JP) | 2019-06-05 | — | — | EP | disclosed |
| US-20170217889-A1 | 4-SUBSTITUTED PYRIDINE-2,6-DICARBOXYLIC ACID DERIVATIVES AND METHOD OF PREPARING SAME | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217889-A1 | 4-SUBSTITUTED PYRIDINE-2,6-DICARBOXYLIC ACID DERIVATIVES AND METHOD OF PREPARING SAME | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-3191451-A1 | 4-SUBSTITUTED PYRIDINE-2,6-DICARBOXYLIC ACID DERIVATIVES AND METHOD OF PREPARING SAME | Okinawa Institute of Science and Technology School Corporation (JP) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016038890-A1 | 4-SUBSTITUTED PYRIDINE-2,6-DICARBOXYLIC ACID DERIVATIVES AND METHOD OF PREPARING SAME | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217889-A1 | 4-SUBSTITUTED PYRIDINE-2,6-DICARBOXYLIC ACID DERIVATIVES AND METHOD OF PREPARING SAME | PDK2, PKD1, PDHA2 | RAB9A 2564/4885GAA 1601/4885CA9 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.